Healthier Markets. Healthier Lives.

Innovative finance for affordable and accessible healthcare

We are a social finance company with a difference. We are motivated by purpose, not profit.

Using innovative finance tools, we secure lower prices and sustainable supply of medical products for people in low- and middle-income countries. Our work combines commercial insight and rigour with a relentless pursuit of health impact.

MedAccess is an independent company, wholly owned by British International Investment.

OUR IMPACT

Read our 2021 Annual Review

In 2021, we provided three new guarantees and launched our 2021-2025 strategy. Find out how our new and existing guarantees helped protect and improve the health of millions of people.

Find out more

Two scientists using a Hologic Panther machine

ABOUT US

Who we are

We believe in a world where everyone can access the medicines and healthcare products they need to lead healthy lives.

Learn more

OUR WORK

Innovative finance for development

Our innovative finance tools enable manufacturers and procurers to enter into partnerships that increase access to medical products for people who need them.

Learn more

Latest News & Insight

News – 21 Sep '22

MedAccess expects to deploy more than $150 million to support Global Fund’s fight against HIV, TB and malaria

MedAccess CEO Michael Anderson announced the social finance company’s intention at an event hosted in New York ahead of the Global Fund’s replenishment pledging session.

News – 08 Sep '22

P. vivax malaria elimination efforts boosted by new agreement to expand access to G6PD testing

MedAccess, PATH, and SD Biosensor today announced a new partnership aimed at advancing progress towards elimination of P. vivax malaria.

Insight – 02 Aug '22

The reality of undiagnosed syphilis for mothers and babies

Nigeria is ramping up the use of a test which can detect both HIV and syphilis simultaneously. But why is this test so vital to the health of mothers and their babies?

News – 01 Aug '22

Partners announce reduced price for patient-friendly tuberculosis preventive treatments

New lower prices negotiated as partners aim to increase access to short-course tuberculosis preventive treatments.